Insulet Corporation's Board of Directors appointed Ashley McEvoy as President and Chief Executive Officer, effective immediately. Ms. McEvoy also joined the Board of Directors, succeeding Jim Hollingshead, who mutually agreed with the Board to cease his employment effective April 28, 2025, and resigned from the Board.
Ms. McEvoy brings nearly three decades of healthcare leadership experience, including serving as Executive Vice President and Worldwide Chairman of Johnson & Johnson’s MedTech business. She also has deep diabetes experience, having previously served as Group Chairman of Johnson & Johnson Vision and Diabetes Care.
Insulet expects to exceed its previously provided first-quarter revenue guidance and intends to raise guidance for the full year 2025. The planned Investor Day for June 5, 2025, has been postponed and will be rescheduled in light of the CEO transition.
The appointment of a new CEO with extensive MedTech and diabetes care experience, particularly from a large diversified player like Johnson & Johnson, signals a strategic shift aimed at accelerating growth and innovation. The immediate positive outlook on Q1 revenue and raised full-year guidance, despite the leadership change, indicates confidence in the company's trajectory. This transition is expected to drive enhanced innovation and global expansion.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.